Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C-C motif) ligand 2 expression in tumor-associated macrophage

被引:50
作者
Choi, Hee-Jin
Choi, Hee-Jung
Chung, Tae-Wook
Ha, Ki-Tae
机构
[1] Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan 626870, Gyeongsangnam D, South Korea
[2] Pusan Natl Univ, Hlth Aging Korean Med Res Ctr, Yangsan 626870, Gyeongsangnam D, South Korea
基金
新加坡国家研究基金会;
关键词
TAMs; IL-4; Luteolin; STAT6; CCL2; Migration; CHEMOATTRACTANT PROTEIN-1 MCP-1; DIETARY FLAVONOIDS; TYROSINE KINASE; IN-VIVO; CANCER; MICROENVIRONMENT; PROGRESSION; METASTASIS; CCL2;
D O I
10.1016/j.bbrc.2016.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor-associated macrophages (TAMs) play pivotal roles in the progression of cancer. In order to investigate a novel candidate that inhibits the tumor-supporting M2-like phenotype of TAMs, a murine macrophage cell line RAW 264.7 cells were treated with interleukin (IL)-4. Luteolin inhibited phosphorylation of signal transducer and activator of transcription 6 (STAT6), a main downstream signal of IL-4, and reduced the expression of the M2-associated genes. In addition, Luminex multiplex analysis for secreted cytokines revealed that IL-4-enhanced secretion of chemokine (C-C motif) ligand 2 (CCL2) was reduced by luteolin treatment. IL-4-stimulated migration of monocyte, THP-1 cells, was inhibited by luteolin treatment and recovered by recombinant CCL2 supplement. Moreover, luteolin decreased migration of Lewis lung carcinoma cells in a CCL2-dependent manner. Given the important role of the TAM phenotype in the tumor microenvironment, inhibitory effect of luteolin on the monocyte recruitment and cancer migration via suppression of the TAM-secreted CCL2 may suggest a novel therapeutic approach to treat malignant tumors. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 33 条
[1]   Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies [J].
Aleman, Jose O. ;
Farooki, Azeez ;
Girotra, Monica .
ENDOCRINE-RELATED CANCER, 2014, 21 (03) :R247-R259
[2]   Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production [J].
Allavena, P ;
Signorelli, M ;
Chieppa, M ;
Erba, E ;
Bianchi, G ;
Marchesi, F ;
Olimpio, CO ;
Bonardi, C ;
Garbi, A ;
Lissoni, A ;
de Brand, F ;
Jimeno, J ;
D'Incalci, M .
CANCER RESEARCH, 2005, 65 (07) :2964-2971
[3]  
Barbera-Cremades M., 2015, J LEUKOC BI IN PRESS
[4]   Monocyte Chemotactic Protein 1 Promotes Lung Cancer-Induced Bone Resorptive Lesions In Vivo [J].
Cai, Zhong ;
Chen, Qiuyan ;
Chen, Jun ;
Lu, Yi ;
Xiao, Guozhi ;
Wu, Zhihao ;
Zhou, Qinghua ;
Zhang, Jian .
NEOPLASIA, 2009, 11 (03) :228-236
[5]   Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1 [J].
Casagrande, F ;
Darbon, JM .
BIOCHEMICAL PHARMACOLOGY, 2001, 61 (10) :1205-1215
[6]   Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment [J].
Chanmee, Theerawut ;
Ontong, Pawared ;
Konno, Kenjiro ;
Itano, Naoki .
CANCERS, 2014, 6 (03) :1670-1690
[7]   Anti-inflammatory Activity of Saxifragin via Inhibition of NF-κB Involves Caspase-1 Activation [J].
Cheon, Se-Yun ;
Chung, Kyung-Sook ;
Jeon, Eunjin ;
Nugroho, Agung ;
Park, Hee-Jun ;
An, Hyo-Jin .
JOURNAL OF NATURAL PRODUCTS, 2015, 78 (07) :1579-1585
[8]   CCL2 (monocyte chemoattractant protein-1) and cancer [J].
Conti, I ;
Rollins, BJ .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) :149-154
[9]   Monocyte Chemoattractant Protein-1 (MCP-1): An Overview [J].
Deshmane, Satish L. ;
Kremlev, Sergey ;
Amini, Shohreh ;
Sawaya, Bassel E. .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2009, 29 (06) :313-326
[10]   Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells [J].
Fang, Jing ;
Zhou, Qiong ;
Shi, Xiang-lin ;
Jiang, Bing-hua .
CARCINOGENESIS, 2007, 28 (03) :713-723